Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be practicing specific forms of birth control on study treatment, or be post-menopausal for more than 2 years or surgically sterile~* Male or female between 18 and 70 years, inclusive, at time of Screening.~* Chronic HCV-infection prior to study enrollment.~* Screening laboratory result indicating HCV genotype 1-infection.~* Compensated cirrhosis defined as a Child-Pugh Score of less than or equal to 6 at Screening~* Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.~Exclusion Criteria:~* Significant liver disease with any cause other than HCV as the primary cause~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab) at screening.~* Prior therapy with direct acting antiviral agents for the treatment of HCV, including telaprevir and boceprevir.~* Any current or past clinical evidence of Child-Pugh B or C Classification or clinical history of liver decompensation including ascites (noted on physical exam), variceal bleeding or hepatic encephalopathy.~* A positive screening ultrasound for hepatocellular carcinoma (HCC) confirmed with a subsequent CT Scan or MRI during the screening period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
- ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks (Type: EXPERIMENTAL): ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).